Trinity Biotech Announces Management Changes
December 18 2023 - 4:30PM
Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading
developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, today announced the
promotion of John Gillard, our Chief Financial Officer, to
President and Chief Executive Officer, effective immediately.
Des Fitzgerald, who has served as Director of
Corporate Development of Trinity Biotech since October 2022, has
been promoted to Interim Chief Financial Officer, succeeding Mr.
Gillard in that role.
“I am very excited to lead Trinity Biotech, a
company with a rich history of providing important and accessible
healthcare solutions across the globe,” said John Gillard, on his
appointment as Chief Executive Officer. “I intend to focus on
leveraging my background in large scale global technology
organisations to build on the company’s existing capabilities and
to steer the business to attractive new technology horizons, while
commercially optimising our existing portfolio of product areas. As
a team, Trinity’s commitment to innovation and providing access to
modern valuable healthcare solutions internationally is our driving
force as the company moves into its next phase. I look forward to
leading Trinity Biotech towards a future of growth and increased
shareholder value.”
Mr. Gillard has served as Chief Financial
Officer and board member of the company since November 2020. He is
an experienced international business executive, having held senior
roles at Google, SSE plc and ION Investment Group. Mr. Gillard is a
Chartered Accountant having trained at PWC.
Mr. Fitzgerald – a Chartered Accountant - joined
Trinity Biotech in 2022. Prior to that he was a Director at PWC
Canada, specialising in the life sciences industry.
Mr. Gillard succeeds Aris Kekedjian, who is
resigning as Chief Executive Officer and as a member of the Trinity
Board of Directors effective 17 December 2023. Mr. Kekedjian
stated: "I appreciate my experience at Trinity Biotech and wish
everyone at the company success into the future”.
About Trinity Biotech Plc
Trinity Biotech develops, acquires,
manufactures, and markets diagnostic systems, including both
reagents and instrumentation, for the point-of-care and clinical
laboratory segments of the diagnostic market. The products are used
to detect infectious diseases and to quantify the level of
Haemoglobin A1c and other chemistry parameters in serum, plasma and
whole blood. Trinity Biotech sells direct in the United States,
Germany, France, and the U.K. and through a network of
international distributors and strategic partners in over 75
countries worldwide. For further information, please see the
Company's website: www.trinitybiotech.com.
Forward Looking Statements
Certain statements made in this release that are
not historical are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
“estimate”, “project”, “intend”, “expect”, “believe” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks
and uncertainties. Many factors could cause the actual results,
performance or achievements of Trinity Biotech to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements,
including, but not limited to, the results of research and
development efforts, the effect of regulation by the U.S. Food and
Drug Administration and other agencies, the impact of competitive
products, product development commercialization, continued listing
on the Nasdaq Stock Market and technological difficulties. For
additional information regarding these and other risks and
uncertainties associated with Trinity Biotech’s business, reference
is made to our reports filed from time to time with the U.S.
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statements for any reason.
|
|
|
Contact: |
Trinity Biotech plc |
Eric Ribner |
|
Des Fitzgerald |
LifeSci Advisors, LLC |
|
+353-1-2769800 |
+1-646 -751-4363 |
|
|
E-mail:
investorrelations@trinitybiotech.com |
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024